<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-151158" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Thrombopoietin Receptor Agonists</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ijaz</surname>
            <given-names>Anum</given-names>
          </name>
          <aff>Shifa International Hospital ltd Faisalabad</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anum Ijaz declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-151158.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">Thrombopoietin receptor agonists (TPO-RAs) are hematopoietic growth factors that bind to the thrombopoietin receptors on megakaryocytes and hematopoietic stem cells (HSCs), inducing the activation of Janus kinase/signal transducer and activator of transcription (JAK-STAT), mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3-kinase (PI3K-AKT) pathways. These signaling cascades stimulate the proliferation and maturation of megakaryocytes while inhibiting their apoptosis, ultimately leading to an augmentation in platelet counts.</p>
        <p>After the discovery that the thrombopoietin receptor (Mpl) is the optimal target for developing new drugs to treat thrombocytopenia, second-generation non-immunogenic thrombopoietic agents have been developed and approved by the U.S. Food and Drug Administration (FDA).<xref ref-type="bibr" rid="article-151158.r1">[1]</xref>&#x000a0;Currently, 4 drugs are used clinically in the treatment of thrombocytopenia&#x02014;eltrombopag, lusutrombopag, avatrombopag, and romiplostim. The first 3 drugs are peptide-like molecules, whereas the last one is a recombinant polypeptide. Clinical indications vary among these agents due to mechanistic differences; however, all drugs increase platelet count in patients with thrombocytopenia due to various etiologies.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Eltrombopag and romiplostim effectively address thrombocytopenia in adult patients with immune thrombocytopenia (ITP) refractory to immunosuppression, splenectomy, and intravenous (IV) immunoglobulins.<xref ref-type="bibr" rid="article-151158.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Eltrombopag is used to treat severe aplastic anemia (SAA) in adults and pediatric patients aged 2&#x000a0;and older.<xref ref-type="bibr" rid="article-151158.r3">[3]</xref><bold>&#x000a0;</bold></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Avatrombopag and lusutrombopag provide a secure and efficient alternative to platelet transfusions for individuals with chronic liver disease (CLD) undergoing invasive procedures.<xref ref-type="bibr" rid="article-151158.r4">[4]</xref><xref ref-type="bibr" rid="article-151158.r5">[5]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Eltrombopag and romiplostim are approved for treating chronic immune thrombocytopenia (CIT) in children aged 1 and older, specifically in cases of ITP lasting over 6 months and exhibiting an inadequate response to corticosteroids, immunoglobulins, or splenectomy.<xref ref-type="bibr" rid="article-151158.r6">[6]</xref><xref ref-type="bibr" rid="article-151158.r7">[7]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Eltrombopag is beneficial in managing antiviral therapy&#x02013;induced bone marrow suppression and thrombocytopenia aggravation in patients with hepatitis C virus (HCV) and advanced fibrosis.<xref ref-type="bibr" rid="article-151158.r8">[8]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Romiplostim is approved for the treatment of hematopoietic syndrome of acute radiation syndrome. Romiplostim has shown efficacy in improving survival rates among adults and pediatric patients, including neonates with acute exposure to myelosuppressive doses of radiation.<xref ref-type="bibr" rid="article-151158.r9">[9]</xref><xref ref-type="bibr" rid="article-151158.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>TPO-RAs can increase platelet count in patients with chemotherapy-induced thrombocytopenia during cancer treatment.<xref ref-type="bibr" rid="article-151158.r11">[11]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The use of TPO-RAs is considered in the treatment of neonatal alloimmune thrombocytopenia, congenital amegakaryocytic thrombocytopenia, chemotherapy-induced thrombocytopenia, and stem cell transplant-associated thrombocytopenia in children.<xref ref-type="bibr" rid="article-151158.r12">[12]</xref><xref ref-type="bibr" rid="article-151158.r13">[13]</xref><xref ref-type="bibr" rid="article-151158.r14">[14]</xref><xref ref-type="bibr" rid="article-151158.r15">[15]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Eltrombopag provides an effective potential treatment option in challenging situations such as thrombocytopenia secondary to myelodysplastic syndromes (MDSs), lymphoproliferative syndromes, and&#x000a0;HSC transplants (HSCTs).</p>
          </list-item>
        </list>
        <p>Romiplostim obtained expedited approval from the FDA in 2008 for its utilization in adults with CIT after undergoing initial testing in healthy volunteers and being supported by preclinical data. This approval followed clinical trials conducted by Bussel et al and Kuter et al.<xref ref-type="bibr" rid="article-151158.r16">[16]</xref> Broadening its application, in 2018, romiplostim secured additional approval for use in children aged 1 and older with ITP lasting over 6 months, specifically in situations where there had been an insufficient response to corticosteroids, immunoglobulins, or splenectomy.<xref ref-type="bibr" rid="article-151158.r17">[17]</xref>&#x000a0;</p>
        <p>In a parallel timeline, a second TPO-RA, eltrombopag, obtained FDA approval in 2011 for adult patients with CIT who demonstrated an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Subsequently, in 2016, its label was extended to include children aged 1 and older with the same condition, based on the findings of 2 randomized placebo-controlled clinical trials&#x02014;PETIT1 and PETIT2.<xref ref-type="bibr" rid="article-151158.r17">[17]</xref> In 2014, the FDA granted approval to eltrombopag for its role in hematopoietic recovery in aplastic anemia cases nonresponsive to immunosuppression. Furthermore, eltrombopag received FDA approval for initiating and maintaining antiviral therapy in patients with hepatitis C&#x02013;related CLD based on the outcomes of two randomized clinical trials&#x02014;ENABLE-1 and ENABLE-2.<xref ref-type="bibr" rid="article-151158.r8">[8]</xref></p>
        <p>Avatrombopag obtained its initial approval in the United States on May 21, 2018, for addressing periprocedural thrombocytopenia in adult patients with CLD based on the pivotal phase 3 trials&#x02014;ADAPT-1 and ADAPT-2. In addition, in September 2011, the FDA granted Orphan Drug Designation to avatrombopag for treating ITP.<xref ref-type="bibr" rid="article-151158.r18">[18]</xref></p>
        <p>The FDA approved lusutrombopag in July 2018 for the treatment of thrombocytopenia in adult patients with&#x000a0;CLD who are scheduled to undergo a procedure. This approval was based on the findings from 2 randomized controlled trials&#x02014;L-PLUS 1 and L-PLUS 2.<xref ref-type="bibr" rid="article-151158.r18">[18]</xref></p>
        <p>Clinical studies investigating the use of TPO-RAs in CIT, particularly in real-world scenarios, recommend romiplostim as the most widely supported option. In fact, according&#x000a0;to the National Comprehensive Cancer Network guidelines, romiplostim stands as the recommended TPO-RA for managing CIT outside of clinical trial contexts. The ongoing phases 2 and 3 of the clinical trials evaluate romiplostim and oral TPO-RAs for the treatment of persistent CIT, with the expectation that these trials will introduce more therapeutic choices for individuals with CIT.<xref ref-type="bibr" rid="article-151158.r19">[19]</xref></p>
        <p>Although a limited number of case reports have suggested the potential utility of romiplostim in addressing neonatal alloimmune thrombocytopenia, congenital amegakaryocytic thrombocytopenia, chemotherapy-induced thrombocytopenia, and stem cell transplant-related thrombocytopenia in pediatric patients, it is crucial to recognize that comprehensive clinical trials are presently underway to collect and publish more definitive data.<xref ref-type="bibr" rid="article-151158.r6">[6]</xref></p>
      </sec>
      <sec id="article-151158.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>TPO-RAs are second-generation, non-immunogenic thrombopoietin growth factors that&#x000a0;bind to and activate thrombopoietin receptors similar to thrombopoietin.&#x000a0;Thrombopoietin receptors are found in various hematopoietic tissues, ranging from stem cells to mature platelets. Activation<bold><italic toggle="yes">&#x000a0;</italic></bold>of thrombopoietin receptors&#x000a0;initiates multiple downstream signaling pathways, including JAK2/STAT5, MAPK, PI3K-AKT, MAPK kinase-extracellular signal&#x02013;regulated kinase (MEK/ERK), and p38. Collectively, these pathways contribute to cell growth, maturation, and the prevention of platelet apoptosis, ultimately leading to an increase in platelet count. The TPO-RAs&#x02014;eltrombopag, avatrombopag, and lusutrombopag&#x02014;bind to the transmembrane domain of the thrombopoietin receptor, whereas romiplostim competitively binds to the receptor's extracellular domain.<xref ref-type="bibr" rid="article-151158.r20">[20]</xref> However, the mechanism of thrombopoietin receptor activation varies among TPO-RAs, ultimately activating different signaling pathways.</p>
        <p>In addition to their ability to increase platelet counts by stimulating thrombopoietin receptors and inducing gene transcription, eltrombopag and romiplostim demonstrate immunoregulatory properties, leading to heightened levels of regulatory T cells in individuals with ITP. This particular effect is facilitated by transforming growth factor-&#x003b2; (TGF-&#x003b2;), which is notably abundant in megakaryocytes and platelets.<xref ref-type="bibr" rid="article-151158.r21">[21]</xref></p>
        <p>In addition to its effect on the thrombopoietin receptor, eltrombopag exhibits off-target effects. Clinical evidence indicating a trilineage and bilineage impact in patients with SAA undergoing eltrombopag therapy suggests that eltrombopag may exert a direct stimulatory effect on HSCs or immature progenitor cells.&#x000a0;Eltrombopag has been observed to exert DNA repair effects through non-homologous end-joining and stimulate the activity of DNA-dependent protein kinase. These actions mimic the DNA repair capabilities exhibited by endogenous thrombopoietin. This fact is supported by a notable improvement in cell viability following gamma irradiation in granulocyte colony-stimulating factor CD34+ cells and improved treatment responses observed in patients diagnosed with Fanconi anemia following eltrombopag therapy.</p>
        <p>Eltrombopag's possession of a central metal-chelating group enables it to chelate both calcium and iron, thereby influencing intracellular iron balance. As cancer cells are sensitive to perturbations in intracellular iron levels, the anticancer properties of eltrombopag can be attributed, at least partially, to its iron-chelating capabilities. Moreover, the growth-inhibiting effect of eltrombopag on both myeloid and non-myeloid cell lineages highlights its direct influence on restraining cancer cell proliferation. Nevertheless, further clinical investigations are warranted to delve deeper into this research area.<xref ref-type="bibr" rid="article-151158.r21">[21]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;All 4 TPO-RAs are absorbed from the gastrointestinal tract, and food intake has no effect except for eltrombopag. High-fat and calcium-rich foods hinder eltrombopag absorption. In addition, coadministration with polyvalent cations such as antacids and mineral supplements (iron, calcium, aluminum, magnesium, selenium, and zinc) reduces eltrombopag absorption. On the contrary, avatrombopag, romiplostim, and lusutrombopag can be taken with or without food, as they are absorbed from the gastrointestinal tract&#x000a0;regardless of food intake.</p>
        <p><bold>Distribution:</bold>&#x000a0;The high plasma protein binding is a common characteristic among all TPO-RAs,&#x000a0;with eltrombopag at &#x02265; 99.9%, lusutrombopag at &#x02265;99.9%, and avatrombopag at &#x02265;96%. This binding characteristic contributes to their limited volume of distribution, as evidenced by lusutrombopag with a mean volume of distribution (% CV) of 23.5%, avatrombopag at 25%, and eltrombopag ranging from 50% to 79% of plasma concentration.</p>
        <p><bold>Metabolism:</bold>&#x000a0;TPO-RAs undergo extensive metabolism primarily by liver enzymes, except for romiplostim, which is metabolized by reticuloendothelial cells. Eltrombopag undergoes metabolism via the isoenzymes CYP1A2 and CYP2C9, as well as uridine diphosphate-glucuronosyltransferase (UGT)-1A1 and UGT1A3. Avatrombopag is predominantly metabolized by the liver's cytochrome P450 system (CYP3A4 and CYP2C9). Lusutrombopag undergoes minimal liver metabolism, primarily through oxidation and glucuronidation.<xref ref-type="bibr" rid="article-151158.r22">[22]</xref></p>
        <p><bold>Elimination:</bold>&#x000a0;The primary route of excretion for avatrombopag, eltrombopag, and lusutrombopag is through feces, with minimal urinary excretion. Avatrombopag exhibits the highest fecal excretion at 88%, followed by lusutrombopag at 83% and eltrombopag at 59%. In contrast, romiplostim is cleared through reticuloendothelial cells following recycling by FcRn receptors on endothelial cells. The half-life of avatrombopag is around 19 hours, which is comparable to eltrombopag (21 to 32 hours) and lusutrombopag (27 hours). On the other hand, the half-life of romiplostim ranges from 1 to 35 days, with an average of 3.5 days.</p>
      </sec>
      <sec id="article-151158.s3" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms</bold>
</p>
        <p>TPO-RAs are available in oral formulations, except for romiplostim, which is exclusively available in injectable form. The prescribed dosage varies based on the specific indications. Notably, evaluating and consistently monitoring the platelet count before initiating treatment and throughout the therapeutic course is imperative to maintain&#x000a0;a platelet count &#x02265;50&#x000d7;10<sup>9</sup>/L. Regularly monitoring liver function tests (LFTs) is advisable during eltrombopag treatment. Dosage adjustments for all TPO-RAs are based on platelet count, considerations related to ethnicity, and LFTs for eltrombopag. Although all TPO-RAs can be taken with food, eltrombopag should be administered on an empty stomach&#x02014;1 hour before or 2 hours after a meal&#x02014;with no coadministration of divalent cations within 4 hours.</p>
        <p>
<bold>Available Dosage Strengths</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Eltrombopag is available in tablet form with strengths of 12.5 mg, 25 mg, 50 mg, 75 mg, and 100 mg.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Avatrombopag is available in tablet&#x000a0;form with a strength&#x000a0;of 20 mg.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lusutrombopag is available in&#x000a0;tablet&#x000a0;form with a strength&#x000a0;of 3 mg.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Romiplostim is available in vials containing 250 and 500 mcg/mL concentrations. The standard initial dosage is 1 mcg/kg administered weekly through subcutaneous injection, with the option to increase to a maximum of 10 mcg/kg, considering tolerance and therapeutic efficacy.</p>
          </list-item>
        </list>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p><bold>ITP in adults</bold>: According to the American&#x000a0;Society of Hematology (ASH) 2019 guidelines for ITP, individuals who are dependent or unresponsive to corticosteroids and have had ITP for at least 3 months should consider TPO-RAs, splenectomy, or rituximab as second-line treatments. Although the guidelines advocate for personalized decision-making, the preference is for TPO-RAs such as romiplostim and eltrombopag over rituximab and splenectomy.<xref ref-type="bibr" rid="article-151158.r23">[23]</xref>&#x000a0;The International Consensus report suggested avatrombopag alongside romiplostim and eltrombopag as TPO-RAs. This stands in contrast to the ASH guidelines, which did not include avatrombopag due to the absence of regulatory approval.<xref ref-type="bibr" rid="article-151158.r24">[24]</xref></p>
        <p>The dosage recommendations for TPO-RAs in CIT are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Avatrombopag is initiated with a once-daily 20 mg tablet, and the maximum daily dosage is 40 mg.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Eltrombopag is initiated at 50 mg once daily, with a maximum increase to 75 mg/d.&#x000a0;Notably,&#x000a0;for individuals with hepatic impairment and patients of East Asian ethnicity (Chinese, Japanese, Taiwanese, and Korean), the initial dose is 25 mg instead of 50 mg.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The initial dosage of romiplostim is 1 &#x003bc;g/kg subcutaneously. Weekly increments of 1&#x003bc;g/kg are made until the maximum dose limit of 10 &#x003bc;g/kg per week is achieved. All the dose increments are made until the desired platelet count of &#x02265;50&#x000d7;10<sup>9</sup>/L is achieved.</p>
          </list-item>
        </list>
        <p><bold>ITP in children</bold>: ITP occurs in 1.9 to 6.4 in 100,000 children. ITP is frequently observed in an otherwise healthy child who presents with the sudden onset of bruising and petechiae and a very low platelet count. The majority of these children resolve spontaneously within a few weeks and do not need treatment.<xref ref-type="bibr" rid="article-151158.r25">[25]</xref> Patients with pediatric ITP may necessitate second-line therapies, including immunosuppressive agents, splenectomy, or, more recently, TPO-RAs. Eltrombopag and romiplostim are the 2 TPO-RAs that have gained approval as second-line treatments in clinical trials conducted in&#x000a0;children&#x000a0;aged 1 or older with ITP of duration 6 months or more.</p>
        <p>The dosage recommendations for TPO-RAs in ITP are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>For children aged 6 or older, the recommended initial dosage of eltrombopag is 50 mg daily, with dosage adjustments made in 25 mg increments. For children between the ages of 1&#x000a0;and 5, the starting dosage of eltrombopag is 25 mg.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Romiplostim is administered subcutaneously, starting at a weekly dosage of 1 &#x003bc;g/kg, and can be increased weekly in increments of 1 &#x003bc;g/kg up to a maximum dosage of 10 &#x003bc;g/kg per week.</p>
          </list-item>
        </list>
        <p><bold>SAA in adults and children:&#x000a0;</bold>Aplastic anemia is a rare disorder that affects the bone marrow and presents with pancytopenia and bone marrow that shows reduced cellularity. The etiology remains unknown in 70% to 80% of cases. According to the British Society for Hematology (BSH) guidelines, the standard treatment for SAA is&#x000a0;HSCT or immunosuppressive therapy, typically involving anti-thymocyte globulin plus cyclosporin.<xref ref-type="bibr" rid="article-151158.r26">[26]</xref>&#x000a0;However, the lack of sufficient response to a second course of immunosuppressive therapy has led to the development of second-line therapy options, such as TPO-RAs. Due to its direct stimulation of bone marrow progenitor cells, eltrombopag has demonstrated significant hematopoietic recovery in SAA by inducing multilineage hematopoiesis.<xref ref-type="bibr" rid="article-151158.r3">[3]</xref><xref ref-type="bibr" rid="article-151158.r27">[27]</xref></p>
        <p>The recommended doses for eltrombopag in refractory SAA for both adults and pediatric patients are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>In cases of SAA refractory to first-line treatment, the initial dosage of eltrombopag is 50 mg once daily, with a maximum allowable dose increment of up to 150 mg daily.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Eltrombopag is used as a first-line therapy adjunct to immunosuppression in pediatric SAA. The&#x000a0;initial dosage for pediatric patients aged 2 to 5 is 2.5 mg/kg, for 6 to 11 is 75 mg, and for 12 or older is 150 mg, administered in conjunction with the immunosuppressive regimen.</p>
          </list-item>
        </list>
        <p><bold>Thrombocytopenia in hepatitis C-induced CLD</bold>: Thrombocytopenia, as a complication of&#x000a0;CLD associated with HCV infection, is an important limiting factor in the initiation and maintenance of peginterferon-based antiviral therapy. This therapy has a significant myelosuppressive effect, potentially aggravating thrombocytopenia.<xref ref-type="bibr" rid="article-151158.r28">[28]</xref>&#x000a0;Eltrombopag is a safe and cost-effective alternative to platelet transfusion, steroids, IV immunoglobulins, splenectomy, and splenic artery embolization for thrombocytopenia in patients with hepatitis C.<xref ref-type="bibr" rid="article-151158.r29">[29]</xref></p>
        <p>The recommended dosage for eltrombopag is initiated at 25 mg once daily, with a maximum dosage of up to 100 mg daily. Dosage adjustments are made&#x000a0;to maintain the platelet count above the level required to initiate antiviral therapy (&#x0003e;25,000 cells per &#x000b5;L).</p>
        <p><bold>Invasive procedures in CLD</bold>: Patients with&#x000a0;CLD frequently require invasive therapeutic and diagnostic procedures, such as variceal band ligation, liver biopsies, or percutaneous procedures, for hepatocellular carcinoma. This makes the management of periprocedural bleeding risk a common clinical consideration. Platelet counts&#x000a0;of 50,000 to 60,000/&#x003bc;L are deemed safe before most invasive procedures in patients with liver cirrhosis, as per the 2009 guidelines provided by the American Association for the Study of Liver Diseases for percutaneous liver biopsy.<xref ref-type="bibr" rid="article-151158.r30">[30]</xref></p>
        <p>The treatment options for thrombocytopenia in CLD include platelet transfusions, splenectomy, splenic artery embolization, and transjugular intrahepatic portosystemic stent (TIPS) placement. However, each of these interventions comes with specific limitations and associated risks. Avatrombopag and lusutrombopag have specifically been shown to be effective alternatives to the conventional treatment options mentioned above. The FDA recommends the following doses because impaired production of thrombopoietin may contribute to the development of thrombocytopenia in advanced-stage liver disease.<xref ref-type="bibr" rid="article-151158.r31">[31]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>According to FDA guidelines, patients are recommended to initiate lusutrombopag 8 to 14 days before the scheduled procedure, with the procedure ideally conducted 2 to 8 days after the last dose. The prescribed dosage is 3 mg orally once daily for a duration of 7 days.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Avatrombopag should be administered orally for 5 days, commencing 10 to 13 days before the scheduled procedure, depending on the platelet count. The recommended dosage is 60 mg (3 tablets) once daily for platelet counts &#x0003c;40&#x000d7;10<sup>9</sup>/L and 40 mg (2 tablets) once daily for platelet counts between 40&#x000a0;to&#x000a0;50&#x000d7;10<sup>9</sup>/L.</p>
          </list-item>
        </list>
        <p><bold><bold>Hematopoietic syndrome due to acute radiation exposure:</bold></bold>&#x000a0;The recommended dosage of romiplostim is 10 mcg/kg, administered via subcutaneous injection. Immediate administration is advised upon suspected or confirmed exposure to radiation levels exceeding 2 gray (Gy).<xref ref-type="bibr" rid="article-151158.r9">[9]</xref> Romiplostim should be administered regardless of the availability of the complete blood count. The patient's absorbed whole-body radiation dose or the extent of radiation exposure should be estimated using information provided by public health authorities, biodosimetry if available, or clinical markers such as the onset of vomiting or kinetics of lymphocyte depletion.<xref ref-type="bibr" rid="article-151158.r32">[32]</xref><xref ref-type="bibr" rid="article-151158.r33">[33]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>Lusutrombopag and avatrombopag can be used in mild-to-moderate liver impairment cases without requiring any dosage adjustments. However, caution is advised in severe hepatic impairment, such as CLD, which results in an apparent high central volume of the drug. Moreover, severe hepatic impairment (Child-Pugh C) is an absolute contraindication for lusutrombopag use. Notably, modifications to the dose of eltrombopag are necessary in cases of moderate-to-severe hepatic impairment. This adjustment is because 60% of the drug undergoes metabolism in the liver, resulting in an increase in the drug's plasma level proportionate to the decline in liver function.<xref ref-type="bibr" rid="article-151158.r34">[34]</xref> In contrast, the pharmacokinetics of romiplostim remain unaffected in cases of mild to moderate hepatic impairment, as its clearance depends on the reticuloendothelial system.</p>
        <p><bold>Renal impairment:</bold> A population pharmacokinetic analysis has established that mild renal impairment (creatinine clearance 60 to &#x0003c;90 mL/min) and moderate impairment (creatinine clearance 30 to 60 mL/min) do not lead to clinically significant alterations in the pharmacokinetics of TPO-RAs. Nevertheless, there is a lack of comprehensive clinical data regarding the impact of severe renal impairment on the pharmacokinetics of TPO-RAs. Therefore, specific dosage adjustments for severe renal impairment have not been recommended. Nonetheless, it is essential to emphasize that individuals with impaired renal function who are prescribed TPO-RAs should undergo close monitoring for potential adverse drug reactions.</p>
        <p><bold>Pregnancy considerations:</bold> Administering eltrombopag and romiplostim throughout all trimesters of pregnancy appears to be relatively safe. However, eltrombopag treatment seems to be associated with low fetal birth weight, particularly when administered during the first or second trimester.&#x000a0;Additional research is needed to determine the safety profile of eltrombopag and romiplostim during pregnancy and to categorize TPO-RAs as safe or hazardous.<xref ref-type="bibr" rid="article-151158.r35">[35]</xref>&#x000a0;Notably, the FDA has not approved the use of TPO-RAs during pregnancy. According to the ASH guidelines, thrombocytopenia during pregnancy should be addressed at a platelet count of 10,000/&#x000b5;L at any time or below 30,000/&#x000b5;L in the second or third trimester or when hemorrhage is present. The ASH recommends IV immunoglobulins as the first-line treatment for severe thrombocytopenia or thrombocytopenic hemorrhage in the third trimester.<xref ref-type="bibr" rid="article-151158.r36">[36]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>The available data do not provide a definitive recommendation on using TPO-RAs during lactation. The benefits versus risks must be carefully assessed for both the mother and the baby during treatment with romiplostim and eltrombopag. Based on the results of animal-based clinical studies, breastfeeding mothers undergoing avatrombopag and lusutrombopag treatment should discard their breast milk and resume breastfeeding after 2 weeks and 28 days following their last dosage of these medications, respectively. Persistent thrombocytosis in a neonate has been reported, likely attributed to the transmission of eltrombopag through breastfeeding.<xref ref-type="bibr" rid="article-151158.r37">[37]</xref></p>
        <p><bold>Pediatric patients</bold>: Eltrombopag and romiplostim are currently approved for use in pediatric patients.<xref ref-type="bibr" rid="article-151158.r6">[6]</xref><xref ref-type="bibr" rid="article-151158.r38">[38]</xref>&#x000a0;The dosage regimens are as described above.</p>
        <p><bold>Older patients:&#x000a0;</bold>Analysis of outcomes from randomized clinical trials involving individuals of various age categories diagnosed with ITP has revealed significant distinctions in the pharmacokinetics and pharmacodynamics of eltrombopag and romiplostim between younger and older groups. Conversely, the clinical investigations about avatrombopag and lusutrombopag, including older individuals, lack the comprehensive data necessary to formulate specific dosage adjustment guidelines for the older population. Nevertheless, when considering dosage adjustments for older patients, it is essential to exercise caution,&#x000a0;considering the prevalence of chronic illnesses and any concurrent medication regimens.<xref ref-type="bibr" rid="article-151158.r39">[39]</xref></p>
      </sec>
      <sec id="article-151158.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most frequently reported adverse events with TPO-RAs are rebound worsening of thrombocytopenia, thrombocytosis, increased bone marrow reticulin, stimulation of growth of leukemic blasts, reduction in the threshold for platelet activation, abnormal LFTs (eltrombopag), thrombosis, stimulation of growth of solid tumors, antibody formation, stem cell depletion and interactions with other cytokines or hematopoietic growth. While using romiplostim for the treatment of ITP, the other reported adverse effects include arthralgia, myalgia, discomfort in extremities, shoulder pain, dizziness, paresthesia, sleep disturbances, abdominal discomfort, and dyspepsia. In clinical trials evaluating avatrombopag's efficacy in adult patients with CIT, adverse events exceeding a 10% incidence rate included headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis.</p>
        <p>Other common adverse effects observed with eltrombopag are headache, elevated alanine aminotransferase (ALT), elevated aspartate aminotransferase (AST), cataracts, fatigue, increased bilirubin levels, nausea, and diarrhea. In summary, the safety profiles of TPO-RAs are not identical, and specific adverse events such as cataracts and elevated transaminase levels are more commonly associated with eltrombopag. Thrombosis and thromboembolic events (arterial and venous) are associated with romiplostim.<xref ref-type="bibr" rid="article-151158.r40">[40]</xref></p>
        <p>Significant adverse reactions of TPO-RAs are provided below.</p>
        <p><bold>Rebound thrombocytopenia:&#x000a0;</bold>Rebound thrombocytopenia is a phenomenon in which a patient experiences a drop in their platelet count below normal levels after having elevated platelet counts. Among TPO-RAs,&#x000a0;eltrombopag is most commonly associated with rebound thrombocytopenia. Approximately 10% of individuals may experience a transient decrease in platelet count lasting for a period of 1 to 3 weeks before returning to baseline levels. Subsets of patients undergoing a rapid decline in platelet count to levels below 10&#x000d7;10<sup>9</sup>/L within 5 to 7 days face a significant bleeding risk. In such cases, a prudent approach may involve considering a reduction in the dose of medication by 25% to 50%.&#x000a0;Notably, the concern of rebound thrombocytopenia applies specifically to individuals diagnosed with ITP.&#x000a0;<xref ref-type="bibr" rid="article-151158.r41">[41]</xref></p>
        <p><bold>Thrombocytosis:</bold>&#x000a0;Thrombocytosis is a medical condition characterized by an elevated number of platelets in the bloodstream. Both eltrombopag and romiplostim can induce thrombocytosis, with platelet levels exceeding 1000&#x000d7;10<sup>9</sup>/L. Although suspension of either medication is advised when platelet counts surpass 400&#x000d7;10<sup>9</sup>/L, in cases of extreme elevations, occasionally exceeding 800&#x000d7;10<sup>9</sup>/L, clinicians may opt to administer a daily dosage of aspirin at 81 mg as a precautionary measure.</p>
        <p><bold>Thrombosis and thromboembolic complications:</bold>&#x000a0;Thrombosis is the formation of blood clots, and thromboembolism is a specific type of thrombotic complication. Thromboembolism can obstruct blood flow to vital organs or tissues, causing damage or organ failure. The risk of thromboembolic events may be increased relative to placebo in patients receiving romiplostim, particularly in those aged 60 or older, compared to immunosuppressant therapies. Therefore, close monitoring of such patients is necessary to mitigate potential risks.<xref ref-type="bibr" rid="article-151158.r42">[42]</xref></p>
        <p>Romiplostim has demonstrated the ability to reduce the threshold for platelet activation by weak agonists, such as ADP, in standard platelet aggregometry studies, demonstrating a significant 50% reduction in this threshold. Long-term clinical trials lasting 6 months or more and involving avatrombopag or eltrombopag did not indicate an increased rate of thromboembolic events compared to the placebo. However, in patients with CLD receiving eltrombopag, the occurrence of symptomatic portal vein thrombosis has been noted. Furthermore, it is essential to highlight that some of these patients presented additional risk factors for thrombosis, including the presence of hepatocellular carcinoma.<xref ref-type="bibr" rid="article-151158.r24">[24]</xref></p>
        <p>In addition, a randomized placebo-controlled trial revealed that lusutrombopag was associated with portal vein thrombosis as the most common adverse effect.<xref ref-type="bibr" rid="article-151158.r43">[43]</xref>&#x000a0;Hence, the decision to prescribe TPO-RAs to individuals with risk factors for thrombosis should be made after a thorough evaluation of the potential benefits and risks.</p>
        <p><bold>Increase in bone marrow reticulin:</bold>&#x000a0;Patients with acute myeloid leukemia (AML) treated with recombinant human thrombopoietin (rhTPO) experienced increased bone marrow reticulin. In contrast, eltrombopag-treated patients (2.6%) exhibited increased reticulin and collagen. Romiplostim-treated ITP patients demonstrated increased reticulin, which remained within the normal range. Furthermore, the risk of progression to myeloid malignancies in these patients is low. Romiplostim use in patients with MDS exhibited a possible progression to AML, affecting the percentage of patients with circulating blasts exceeding 10%. Discontinuation of romiplostim resulted in no further progression of AML in most patients. These findings underscore the need for cautious evaluation of TPO-RAs in individuals with MDS. Importantly, reticulin fibrosis has not been reported as an adverse effect of avatrombopag use.<xref ref-type="bibr" rid="article-151158.r42">[42]</xref></p>
        <p><bold>Antibody formation:</bold>&#x000a0;The formation of antibodies is a significant concern when using recombinant thrombopoietin agents, particularly pegylated-recombinant human megakaryocyte growth and development factor (PEG-rhMGDF). Clinical studies have reported only 2 patients developing non-neutralizing antibodies against romiplostim.<xref ref-type="bibr" rid="article-151158.r44">[44]</xref>&#x000a0;However, these antibodies later disappeared upon reevaluation and did not appear to affect the platelet count. Following these initial cases, no additional instances of antibody formation have been observed. Current findings indicate that no antibodies developed against eltrombopag. In summary, the formation of neutralizing antibodies appears to be a potential concern specifically associated with romiplostim.</p>
        <p><bold>Cataracts:</bold>&#x000a0;In a pooled analysis, romiplostim users reported up to a 9% increase during an 8-year follow-up, translating to 2.2 cases per 100 patient-years. In contrast, eltrombopag showed a 7% increased risk of cataracts, whereas avatrombopag users did not report this adverse effect.<xref ref-type="bibr" rid="article-151158.r17">[17]</xref>&#x000a0;A routine ocular examination is recommended when taking eltrombopag.</p>
        <p><bold>Transaminase elevation:&#x000a0;</bold>Transaminitis may occur in up to 10% of patients taking eltrombopag, typically within the first year of treatment. Eltrombopag has been associated with hepatic transaminitis, leading to a 5% increase in ALT, a 4% increase in AST, and a 4% increase in bilirubin. In contrast, romiplostim users did not report this adverse event. Unlike eltrombopag, romiplostim and avatrombopag do not necessitate routine monitoring of LFTs during therapy. Furthermore, eltrombopag has demonstrated chelating effects with calcium and iron. Post-marketing reports have indicated hyperpigmentation and skin yellowing among eltrombopag users, resembling a jaundice-like state. Therefore, obtaining LFTs and assessing iron indices is advisable to determine the cause of such discoloration.<xref ref-type="bibr" rid="article-151158.r22">[22]</xref></p>
        <p>
<bold>Drug-Drug Interactions&#x000a0;</bold>
<xref ref-type="bibr" rid="article-151158.r40">[40]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Eltrombopag, as an inhibitor of the organic anion transporting polypeptide OATP1B1 transporter, leads to higher exposure to substances that rely on this transporter, such as benzylpenicillin, atorvastatin, fluvastatin, pravastatin, rosuvastatin, methotrexate, nateglinide, repaglinide, and rifampin. In a preclinical study, the coadministration of rosuvastatin with eltrombopag resulted in a 55% increase in the area under the curve and a 103% increase in the maximum plasma concentration of rosuvastatin. Hence, it is recommended to decrease the dose of rosuvastatin by 50% when coadministered with eltrombopag.<xref ref-type="bibr" rid="article-151158.r45">[45]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Eltrombopag has an affinity for binding to polyvalent cations found in various substances, such as iron, calcium, aluminum, magnesium, selenium, and zinc, found in foods, mineral supplements, and antacids. When coadministered with an antacid containing polyvalent cations (aluminum hydroxide, magnesium carbonate, and sodium alginate), eltrombopag exhibited a significant reduction in systemic exposure. To ensure adequate absorption of eltrombopag, it is essential to avoid taking it within 4 hours of consuming medications or products containing polyvalent cations, such as antacids, dairy products, and mineral supplements.<xref ref-type="bibr" rid="article-151158.r46">[46]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Moderate or strong dual CYP2C9 and CYP3A4 inducers or inhibitors, such as itraconazole, fluconazole, rifampin, and verapamil, may reduce the efficacy of avatrombopag.<xref ref-type="bibr" rid="article-151158.r47">[47]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Based on the data obtained from clinical trials, noteworthy alterations in the pharmacokinetics of lusutrombopag did not exist when it was administered concurrently with cyclosporine&#x02014;an inhibitor of P-glycoprotein and breast cancer resistance protein (BRCP)&#x02014;or when administered alongside an antacid that contains a multivalent cation such as calcium carbonate.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-151158.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The current product labeling in the United States has no absolute contraindications for TPO-RAs.</p>
        <p>
<bold>Precautions</bold>
</p>
        <p>TPO-RAs generally do not have absolute contraindications, except for lusutrombopag, which should be avoided in cases of severe hepatic impairment (Child-Pugh Class C), as indicated in the Japanese prescribing information label for lusutrombopag. However, caution is recommended when prescribing TPO-RAs in specific clinical situations. These situations encompass thrombotic conditions, including cerebrovascular infarction and myocardial infarction, and genetic pro-thrombotic disorders such as Factor V Leiden, prothrombin 20210A mutation, antithrombin deficiency, and protein C or S deficiency.<xref ref-type="bibr" rid="article-151158.r48">[48]</xref><xref ref-type="bibr" rid="article-151158.r49">[49]</xref><xref ref-type="bibr" rid="article-151158.r50">[50]</xref>&#x000a0;In addition, it is crucial to be cautious when using TPO-RAs in patients with moderate-to-severe hepatic impairment.</p>
        <p>
<bold>Box Warnings&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Currently,&#x000a0;eltrombopag has a box warning regarding hepatotoxicity. Clinical trials involving patients with ITP revealed that ALT elevations occurred in approximately 10% to 11% of individuals treated with eltrombopag, compared to 3% to 7% in subjects who received a placebo. Importantly, these elevations were typically mild and temporary, often resolving after discontinuing eltrombopag. In some cases, improvements were observed even when patients continued the medication. Documented cases indicate that serum enzyme elevations may reoccur upon restarting eltrombopag, and in several instances, severe liver issues developed, potentially associated with portal vein thrombosis. Because of these reports, eltrombopag carries a boxed warning concerning hepatotoxicity. This warning underscores the risk of hepatic decompensation, particularly when treating patients with chronic hepatitis C, and advocates for close monitoring of LFTs in such cases. Therefore, monitoring certain liver function markers is recommended to ensure the safe use of eltrombopag. This monitoring should follow these guidelines: Before initiating eltrombopag, assess serum ALT, AST, and bilirubin levels.</p>
          </list-item>
          <list-item>
            <p>During the dosage adjustment phase, which spans the initial 2 weeks, healthcare providers should conduct LFTs every 2 weeks. Once a stable dose is achieved, ongoing monitoring should be carried out every month. In cases where elevated bilirubin levels are detected, it is advisable to consider temporary cessation of the medication. If any abnormal serum liver test results are identified, testing should be repeated within 3 to 5 days for confirmation. In cases where the abnormalities are confirmed, healthcare providers should closely monitor serum liver tests every week until the abnormalities either resolve, stabilize, or return to their baseline levels.</p>
          </list-item>
          <list-item>
            <p>If ALT levels increase to 3 times or more the upper limit of normal and meet one of the following conditions: if they are progressive, persist for at least 4 weeks, are accompanied by an increase in direct bilirubin, or are associated with clinical symptoms of liver injury or signs of hepatic decompensation, discontinuation of eltrombopag is recommended. Although restarting treatment with eltrombopag is not recommended, if the potential benefits of reinitiating eltrombopag treatment outweigh the risk of hepatotoxicity, it should be cautiously reintroduced, with weekly serum liver test monitoring during the dose adjustment phase. If liver test abnormalities persist, worsen, or recur during this period, eltrombopag should be permanently discontinued.<xref ref-type="bibr" rid="article-151158.r22">[22]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-151158.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>For individuals undergoing&#x000a0;avatrombopag, lusutrombopag, romiplostim, and eltrombopag treatments, it is essential to monitor the platelet count before initiating treatment.</p>
        <p>
<bold>Avatrombopag</bold>
</p>
        <p>Following the initiation of avatrombopag treatment, it is recommended to monitor platelet counts once weekly. Once the platelet count reaches 50&#x000d7;10<sup>9</sup>/L, the monitoring frequency should shift to monthly assessments. In the event of treatment discontinuation, it is advised to check platelet counts once a week for a minimum of 4 weeks.<xref ref-type="bibr" rid="article-151158.r40">[40]</xref></p>
        <p>
<bold>Lusutrombopag</bold>
</p>
        <p>For individuals receiving lusutrombopag therapy, assessing the platelet count before initiating treatment and 2 days before any scheduled invasive procedure is crucial.</p>
        <p>
<bold>Romiplostim</bold>
</p>
        <p>When undergoing romiplostim treatment, a complete blood count (CBC) that includes platelet assessment should be performed every week during the initial phase of therapy adjustment. After the dose has been stabilized, a transition to monthly evaluations is recommended. Furthermore, monitoring should persist for 2 weeks after treatment discontinuation.</p>
        <table-wrap id="article-151158.table0" position="float" orientation="portrait">
          <caption>
            <title>Table 1. Dosage Adjustments for Romiplostim as per the FDA Label</title>
          </caption>
          <table style="width: 800px; height: 300px;" border="1" cellspacing="1" cellpadding="10">
            <tbody>
              <tr style="height: 19px;">
                <td style="width: 292px; height: 19px;" rowspan="1" colspan="1">
<bold>Platelet Counts</bold>
</td>
                <td style="width: 416.889px; height: 19px;" rowspan="1" colspan="1">
<bold>Dosage Adjustments for Romiplostim</bold>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 292px; height: 13px;" rowspan="1" colspan="1">&#x0003c;50x10<sup>9</sup>/L</td>
                <td style="width: 416.889px; height: 13px;" rowspan="1" colspan="1">The dose should be increased by 1 mcg/kg.</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 292px; height: 13px;" rowspan="1" colspan="1">&#x0003e; 200x10<sup>9</sup>/L for 2 consecutive weeks</td>
                <td style="width: 416.889px; height: 13px;" rowspan="1" colspan="1">The dose should be reduced by 1 mcg/kg.</td>
              </tr>
              <tr style="height: 4px;">
                <td style="width: 292px; height: 4px;" rowspan="1" colspan="1">&#x0003e;400x10<sup>9</sup>/L</td>
                <td style="width: 416.889px; height: 4px;" rowspan="1" colspan="1">
<p>Romiplostim should not be administered in this case. Ongoing assessment of the platelet count every week is recommended. After the platelet count has decreased to &#x0003c;200x10<sup>9</sup>/L, romiplostim use should be resumed at a reduced dose of 1 mcg/kg.</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Eltrombopag</bold>
</p>
        <p>When utilizing eltrombopag therapy, it is necessary to conduct LFTs, including the evaluation of serum ALT, AST, and bilirubin. These tests should occur before initiating therapy and continue at 2-week intervals during the dosage adjustment phase. Once a stable regimen is achieved, these tests should be conducted monthly. If ALT levels increase beyond 3 times the upper limit of normal after initiating therapy or exceed 3 to 5 times the baseline levels in individuals with elevated ALT before treatment, further attention is warranted, and the treatment should be stopped. Furthermore, regular assessments of clinical hematology parameters, including CBC and peripheral blood smears, should be obtained, and a baseline ocular examination should be initiated as routine monitoring during eltrombopag treatment to rule out cataracts and bone marrow fibrosis development.<xref ref-type="bibr" rid="article-151158.r40">[40]</xref></p>
        <table-wrap id="article-151158.table1" position="float" orientation="portrait">
          <caption>
            <title>Table 2.&#x000a0;Dosage Adjustments for Eltrombopag Based on CBC per FDA Label</title>
          </caption>
          <table style="width: 800.4px; height: 300px;" border="1" cellspacing="1" cellpadding="10">
            <tbody>
              <tr style="height: 5px;">
                <td style="width: 313px; height: 5px;" rowspan="1" colspan="1">
<p><bold>Platelet Counts</bold></p>
</td>
                <td style="width: 450.4px; height: 5px;" rowspan="1" colspan="1">
<p><bold>Dosage Adjustments for Eltrombopag</bold></p>
</td>
              </tr>
              <tr style="height: 3px;">
                <td style="width: 313px; height: 3px;" rowspan="1" colspan="1">
<p>&#x0003c;50x10<sup>9</sup>/L following at least 2 weeks of eltrombopag</p>
</td>
                <td style="width: 450.4px; height: 3px;" rowspan="1" colspan="1">
<p>The daily dosage should be increased by 25 mg to a maximum of 75 mg/d.</p>
</td>
              </tr>
              <tr style="height: 8px;">
                <td style="width: 313px; height: 8px;" rowspan="1" colspan="1">
<p>&#x02265;200x10<sup>9</sup>/L to &#x02264;400x10<sup>9</sup>/L at any time</p>
</td>
                <td style="width: 450.4px; height: 8px;" rowspan="1" colspan="1">
<p>The daily dosage should be gradually reduced by 25 mg. Healthcare providers&#x000a0;should wait for at least 2 weeks to evaluate the effects before making any further adjustments to the dosage.</p>
</td>
              </tr>
              <tr style="height: 8px;">
                <td style="width: 313px; height: 8px;" rowspan="1" colspan="1">
<p>&#x0003e;400x10<sup>9</sup>/L</p>
</td>
                <td style="width: 450.4px; height: 8px;" rowspan="1" colspan="1">&#x000a0;
<p>Eltrombopag should be discontinued in this case, and the frequency of platelet monitoring should be increased up to twice weekly. Once the platelet count drops to &#x0003c;150x10<sup>9</sup>/L, the individual should cautiously reintroduce therapy at a daily dosage reduced by 25 mg.</p>
</td>
              </tr>
              <tr style="height: 4px;">
                <td style="width: 313px; height: 4px;" rowspan="1" colspan="1">
<p>&#x0003e;400x10<sup>9</sup>/L after 2 weeks of therapy at the lowest dose of eltrombopag</p>
</td>
                <td style="width: 450.4px; height: 4px;" rowspan="1" colspan="1">Eltrombopag should be discontinued in this case.</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-151158.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Overdosing with TPO-RAs can lead to an excessive increase in platelet count, resulting in thrombotic or thromboembolic complications.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>There are no known antidotes for TPO-RAs overdosage, except in the case of eltrombopag, where the administration of metal cation-containing preparations (such as calcium, aluminum, and magnesium) can restrict eltrombopag absorption. The recommended course of action in the event of a TPO-RA overdose is to discontinue the treatment, monitor the platelet count, manage any thrombotic conditions based on standard care protocols, and, once the effects of the overdose subside, reintroduce the TPO-RA treatment following the recommended dosing and administration guidelines. It is worth noting that TPO-RAs are highly bound to proteins and have limited renal excretion, making hemodialysis an ineffective method for the treatment of overdosage.<xref ref-type="bibr" rid="article-151158.r40">[40]</xref></p>
      </sec>
      <sec id="article-151158.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The effective management of thrombocytopenia, characterized by a low platelet count and the potential risk of severe hemorrhage, emphasizes the&#x000a0;critical need for prompt diagnosis. This requires a comprehensive approach, with a healthcare team comprising physicians, hematologists, nurses, pharmacists, and other specialized professionals. Patient-centered care, essential for meeting health-quality control standards, depends on effective interprofessional collaboration among these stakeholders.</p>
        <p>The cornerstone of ensuring patient-centered care in the context of thrombocytopenia and using TPO-RAs is the cultivation of interprofessional education. Core competencies in this endeavor encompass defining roles and responsibilities, practicing ethics, resolving conflicts, and fostering effective communication.<xref ref-type="bibr" rid="article-151158.r51">[51]</xref></p>
        <p>The evaluation of the patient's medical history, the root causes of thrombocytopenia, and the patient's overall health have a pivotal role in the management of thrombocytopenia. The healthcare team must judiciously assess the suitability of TPO-RAs as a treatment modality. Before prescribing TPO-RAs, obtaining informed consent is necessary to achieve optimal healthcare outcomes and set realistic goals.<xref ref-type="bibr" rid="article-151158.r52">[52]</xref></p>
        <p>Once the decision to administer TPO-RAs is reached, a cohesive partnership between physicians and pharmacists is indispensable in formulating a customized treatment plan. This plan encompasses the determination of the appropriate dosage, a robust monitoring regimen, and a well-structured follow-up schedule.&#x000a0;Educating the patient about their condition, the intricacies of the treatment plan, potential adverse effects, and the imperative nature of compliance with prescribed therapy hinges on effective communication skills. This communication is pivotal in ensuring proper medication compliance.</p>
        <p>Depending on the patient's response and potential adverse effects, the healthcare team may need to adjust the TPO-RA dosage or explore alternative treatment options. TPO-RAs can increase the risk of thrombosis, necessitating collaborative efforts with specialists such as hematologists, pulmonologists, general surgeons, and critical care experts to enhance quality control measures. Consultation with a hepatologist or gastroenterologist is necessary for drug-induced liver injury.<xref ref-type="bibr" rid="article-151158.r53">[53]</xref>&#x000a0;Ophthalmologist consultation is required if there is a suspicion of cataract.</p>
        <p>Enhancing healthcare team outcomes for patients with thrombocytopenia and undergoing treatment with TPO-RAs mandates an interprofessional approach. This approach centers on patient safety, education, individualized care, the acquisition of requisite diagnostic skills, interdisciplinary cooperation, and adherence to ethical principles to achieve the most favorable outcomes for individuals contending with this condition. Healthcare professionals, including physicians, advanced practice practitioners, hematologists, pharmacists, and nurses, must remain updated with the latest research and treatment guidelines to provide the most efficacious care to their patients.</p>
      </sec>
      <sec id="article-151158.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=151158&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=151158">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/151158/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=151158">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-151158.s10">
        <title>References</title>
        <ref id="article-151158.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuter</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>New thrombopoietic growth factors.</article-title>
            <source>Blood</source>
            <year>2007</year>
            <month>Jun</month>
            <day>01</day>
            <volume>109</volume>
            <issue>11</issue>
            <fpage>4607</fpage>
            <page-range>4607-16</page-range>
            <pub-id pub-id-type="pmid">17289815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonz&#x000e1;lez-L&#x000f3;pez</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Alvarez-Rom&#x000e1;n</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Pascual</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Gonz&#x000e1;lez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Fuentes</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jarque</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-Rus</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-Crespo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bernat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez-Rivas</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Andrade</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Cort&#x000e9;s</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-Nu&#x000f1;ez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Olivera</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Robles</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Rodr&#x000ed;guez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fuertes-Palacio</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Mi&#x000f1;ano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>de Cabo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fisac</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>B&#x000e1;rez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pe&#x000f1;arrubia</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Frade</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Porras</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.</article-title>
            <source>Eur J Haematol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>97</volume>
            <issue>3</issue>
            <fpage>297</fpage>
            <page-range>297-302</page-range>
            <pub-id pub-id-type="pmid">26709028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCormack</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>Eltrombopag: a review of its use in patients with severe aplastic anaemia.</article-title>
            <source>Drugs</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>75</volume>
            <issue>5</issue>
            <fpage>525</fpage>
            <page-range>525-31</page-range>
            <pub-id pub-id-type="pmid">25700916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Terrault</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Izumi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kayali</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Mitrut</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tak</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Hassanein</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.</article-title>
            <source>Gastroenterology</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>155</volume>
            <issue>3</issue>
            <fpage>705</fpage>
            <page-range>705-718</page-range>
            <pub-id pub-id-type="pmid">29778606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hidaka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kurosaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kudo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abiru</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Igura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ishikawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Seike</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Katsube</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ochiai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fukuhara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nagata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kurokawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Osaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Izumi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Imawari</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2019</year>
            <month>May</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>1192</fpage>
            <page-range>1192-1200</page-range>
            <pub-id pub-id-type="pmid">30502505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neunert</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.</article-title>
            <source>Blood Adv</source>
            <year>2019</year>
            <month>Jun</month>
            <day>25</day>
            <volume>3</volume>
            <issue>12</issue>
            <fpage>1907</fpage>
            <page-range>1907-1915</page-range>
            <pub-id pub-id-type="pmid">31239245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>TO</given-names>
              </name>
              <name>
                <surname>Despotovic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Eltrombopag for use in children with immune thrombocytopenia.</article-title>
            <source>Blood Adv</source>
            <year>2018</year>
            <month>Feb</month>
            <day>27</day>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>454</fpage>
            <page-range>454-461</page-range>
            <pub-id pub-id-type="pmid">29487060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Afdhal</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Dusheiko</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Giannini</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Mohsin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rodriguez-Torres</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rugina</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bakulin</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lawitz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shiffman</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Tayyab</surname>
                <given-names>GU</given-names>
              </name>
              <name>
                <surname>Poordad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kamel</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Brainsky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Geib</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vasey</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Patwardhan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Theodore</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.</article-title>
            <source>Gastroenterology</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>146</volume>
            <issue>2</issue>
            <fpage>442</fpage>
            <page-range>442-52.e1</page-range>
            <pub-id pub-id-type="pmid">24126097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Seed</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>An update on romiplostim for treatment of acute radiation syndrome.</article-title>
            <source>Drugs Today (Barc)</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>133</fpage>
            <page-range>133-145</page-range>
            <pub-id pub-id-type="pmid">35274632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bunin</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Javitz</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Gahagen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bakke</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>PY</given-names>
              </name>
            </person-group>
            <article-title>Survival and Hematologic Benefits of Romiplostim After Acute Radiation Exposure Supported FDA Approval Under the Animal Rule.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2023</year>
            <month>Nov</month>
            <day>01</day>
            <volume>117</volume>
            <issue>3</issue>
            <fpage>705</fpage>
            <page-range>705-717</page-range>
            <pub-id pub-id-type="pmid">37224926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Song</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Al-Samkari</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia.</article-title>
            <source>Expert Rev Hematol</source>
            <year>2023</year>
            <month>May</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>365</fpage>
            <page-range>365-375</page-range>
            <pub-id pub-id-type="pmid">37039010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahat</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Talati</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kodish</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Comment on: Use of thrombopoietin receptor agonist (romiplostim) in neonatal autoimmune thrombocytopenia due to maternal immune thrombocytopenia.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>66</volume>
            <issue>6</issue>
            <fpage>e27706</fpage>
            <pub-id pub-id-type="pmid">30854752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodeghiero</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pecci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Balduini</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Thrombopoietin receptor agonists in hereditary thrombocytopenias.</article-title>
            <source>J Thromb Haemost</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>9</issue>
            <fpage>1700</fpage>
            <page-range>1700-1710</page-range>
            <pub-id pub-id-type="pmid">29956472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacobson</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Setty</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Romiplostim for therapy-related thrombocytopenia in pediatric malignancies.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>64</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">28150377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maximova</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zanon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rovere</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Maestro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schillani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Paparazzo</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children.</article-title>
            <source>Int J Hematol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>102</volume>
            <issue>5</issue>
            <fpage>626</fpage>
            <page-range>626-32</page-range>
            <pub-id pub-id-type="pmid">26084627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bussel</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Saleh</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Psaila</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kovaleva</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Meddeb</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kloczko</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hassani</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Arning</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Provan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.</article-title>
            <source>N Engl J Med</source>
            <year>2007</year>
            <month>Nov</month>
            <day>29</day>
            <volume>357</volume>
            <issue>22</issue>
            <fpage>2237</fpage>
            <page-range>2237-47</page-range>
            <pub-id pub-id-type="pmid">18046028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghanima</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rodeghiero</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Godeau</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bussel</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Thrombopoietin receptor agonists: ten years later.</article-title>
            <source>Haematologica</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>104</volume>
            <issue>6</issue>
            <fpage>1112</fpage>
            <page-range>1112-1123</page-range>
            <pub-id pub-id-type="pmid">31073079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clemons Bankston</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Al-Horani</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>New Small Molecule Drugs for Thrombocytopenia: Chemical, Pharmacological, and Therapeutic Use Considerations.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>Jun</month>
            <day>20</day>
            <volume>20</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">31226783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Samkari</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2022</year>
            <month>Dec</month>
            <day>09</day>
            <volume>2022</volume>
            <issue>1</issue>
            <fpage>286</fpage>
            <page-range>286-295</page-range>
            <pub-id pub-id-type="pmid">36485134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bussel</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Soff</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Balduzzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Semple</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>A Review of Romiplostim Mechanism of Action and Clinical Applicability.</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2021</year>
            <volume>15</volume>
            <fpage>2243</fpage>
            <page-range>2243-2268</page-range>
            <pub-id pub-id-type="pmid">34079225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bussel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kulasekararaj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Steidl</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Semple</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Will</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms and therapeutic prospects of thrombopoietin receptor agonists.</article-title>
            <source>Semin Hematol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>56</volume>
            <issue>4</issue>
            <fpage>262</fpage>
            <page-range>262-278</page-range>
            <pub-id pub-id-type="pmid">31836033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r22">
          <label>22</label>
          <element-citation publication-type="book">
            <chapter-title>Thrombopoietin Receptor Agonists</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>12</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">31643431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neunert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Terrell</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Buchanan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cines</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cuker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Despotovic</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Grace</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>K&#x000fc;hne</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kuter</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>McCrae</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Pruitt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shimanek</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Vesely</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>American Society of Hematology 2019 guidelines for immune thrombocytopenia.</article-title>
            <source>Blood Adv</source>
            <year>2019</year>
            <month>Dec</month>
            <day>10</day>
            <volume>3</volume>
            <issue>23</issue>
            <fpage>3829</fpage>
            <page-range>3829-3866</page-range>
            <pub-id pub-id-type="pmid">31794604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Provan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Bussel</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gernsheimer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ghanima</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Godeau</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-L&#x000f3;pez</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Grainger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kruse</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Michel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Newland</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Pavord</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rodeghiero</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Scully</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tomiyama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Zaja</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kuter</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Updated international consensus report on the investigation and management of primary immune thrombocytopenia.</article-title>
            <source>Blood Adv</source>
            <year>2019</year>
            <month>Nov</month>
            <day>26</day>
            <volume>3</volume>
            <issue>22</issue>
            <fpage>3780</fpage>
            <page-range>3780-3817</page-range>
            <pub-id pub-id-type="pmid">31770441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neunert</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Buchanan</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Imbach</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bolton-Maggs</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Neufeld</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vesely</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Adix</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Blanchette</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>K&#x000fc;hne</surname>
                <given-names>T</given-names>
              </name>
              <collab>Intercontinental Cooperative ITP Study Group Registry II Participants</collab>
            </person-group>
            <article-title>Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS).</article-title>
            <source>Blood</source>
            <year>2013</year>
            <month>May</month>
            <day>30</day>
            <volume>121</volume>
            <issue>22</issue>
            <fpage>4457</fpage>
            <page-range>4457-62</page-range>
            <pub-id pub-id-type="pmid">23550040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marsh</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ball</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Cavenagh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Darbyshire</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dokal</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gordon-Smith</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Keidan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Laurie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mercieca</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Killick</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>JA</given-names>
              </name>
              <collab>British Committee for Standards in Haematology</collab>
            </person-group>
            <article-title>Guidelines for the diagnosis and management of aplastic anaemia.</article-title>
            <source>Br J Haematol</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>147</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-70</page-range>
            <pub-id pub-id-type="pmid">19673883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olnes</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Scheinberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Calvo</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Desmond</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dumitriu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Parikh</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Soto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Biancotto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lozier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Dunbar</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Eltrombopag and improved hematopoiesis in refractory aplastic anemia.</article-title>
            <source>N Engl J Med</source>
            <year>2012</year>
            <month>Jul</month>
            <day>05</day>
            <volume>367</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-9</page-range>
            <pub-id pub-id-type="pmid">22762314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fouad</surname>
                <given-names>YM</given-names>
              </name>
            </person-group>
            <article-title>Chronic hepatitis C-associated thrombocytopenia: aetiology and management.</article-title>
            <source>Trop Gastroenterol</source>
            <year>2013</year>
            <season>Apr-Jun</season>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>58</fpage>
            <page-range>58-67</page-range>
            <pub-id pub-id-type="pmid">24377151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Afdhal</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>McHutchison</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Review article: pharmacological approaches for the treatment of thrombocytopenia in patients with chronic liver disease and hepatitis C infection.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>26 Suppl 1</volume>
            <fpage>29</fpage>
            <page-range>29-39</page-range>
            <pub-id pub-id-type="pmid">17958517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rockey</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Caldwell</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>AD</given-names>
              </name>
              <collab>American Association for the Study of Liver Diseases</collab>
            </person-group>
            <article-title>Liver biopsy.</article-title>
            <source>Hepatology</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>49</volume>
            <issue>3</issue>
            <fpage>1017</fpage>
            <page-range>1017-44</page-range>
            <pub-id pub-id-type="pmid">19243014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koruk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Onuk</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Ak&#x000e7;ay</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Savas</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis, and its relationship with circulating thrombocyte counts.</article-title>
            <source>Hepatogastroenterology</source>
            <year>2002</year>
            <season>Nov-Dec</season>
            <volume>49</volume>
            <issue>48</issue>
            <fpage>1645</fpage>
            <page-range>1645-8</page-range>
            <pub-id pub-id-type="pmid">12397754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wathen</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Eder</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Horwith</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Using biodosimetry to enhance the public health response to a nuclear incident.</article-title>
            <source>Int J Radiat Biol</source>
            <year>2021</year>
            <volume>97</volume>
            <issue>sup1</issue>
            <fpage>S6</fpage>
            <page-range>S6-S9</page-range>
            <pub-id pub-id-type="pmid">32909884</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ellsworth</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Yalamanchali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Comprehensive Analysis of the Kinetics of Radiation-Induced Lymphocyte Loss in Patients Treated with External Beam Radiation Therapy.</article-title>
            <source>Radiat Res</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>193</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <page-range>73-81</page-range>
            <pub-id pub-id-type="pmid">31675264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bauman</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wire</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Effect of hepatic or renal impairment on eltrombopag pharmacokinetics.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2011</year>
            <month>May</month>
            <volume>51</volume>
            <issue>5</issue>
            <fpage>739</fpage>
            <page-range>739-50</page-range>
            <pub-id pub-id-type="pmid">20663991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Howaidi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>AlRajhi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Howaidi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>AlNajjar</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Tailor</surname>
                <given-names>IK</given-names>
              </name>
            </person-group>
            <article-title>Use of Thrombopoietin Receptor Agonists in Pregnancy: A Review of the Literature.</article-title>
            <source>Hematol Oncol Stem Cell Ther</source>
            <year>2022</year>
            <month>Mar</month>
            <day>01</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-6</page-range>
            <pub-id pub-id-type="pmid">34153229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <article-title>Diagnosis and treatment of idiopathic thrombocytopenic purpura. American Society of Hematology ITP Practice Guideline Panel.</article-title>
            <source>Am Fam Physician</source>
            <year>1996</year>
            <month>Dec</month>
            <volume>54</volume>
            <issue>8</issue>
            <fpage>2437</fpage>
            <page-range>2437-47, 2451-2</page-range>
            <pub-id pub-id-type="pmid">8961844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r37">
          <label>37</label>
          <element-citation publication-type="book">
            <chapter-title>Eltrombopag</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">34813256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ehrlich</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Kwitkowski</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Reaman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Nie</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pazdur</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Farrell</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>U.S. Food and Drug Administration approval summary: Eltrombopag for the treatment of pediatric patients with chronic immune (idiopathic) thrombocytopenia.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>64</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">28627134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palandri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bartoletti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ferretti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ruggeri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lucchini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Carrai</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Barcellini</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Patriarca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rivolti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Consoli</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Cantoni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oliva</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Chiurazzi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Caocci</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Giuffrida</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Borchiellini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Auteri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Baldacci</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Carli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nicolosi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sutto</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Carpenedo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cavo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mazzucconi</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Zaja</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>De Stefano</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rodeghiero</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vianelli</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia.</article-title>
            <source>Blood</source>
            <year>2021</year>
            <month>Aug</month>
            <day>19</day>
            <volume>138</volume>
            <issue>7</issue>
            <fpage>571</fpage>
            <page-range>571-583</page-range>
            <pub-id pub-id-type="pmid">33889952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gilreath</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bubalo</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.</article-title>
            <source>Drugs</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>81</volume>
            <issue>11</issue>
            <fpage>1285</fpage>
            <page-range>1285-1305</page-range>
            <pub-id pub-id-type="pmid">34160821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuter</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Bussel</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Pullarkat</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gernsheimer</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Senecal</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Aledort</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Kessler</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Sanz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Liebman</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Slovick</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>de Wolf</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Bourgeois</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Guthrie</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Newland</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wasser</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Hamburg</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Grande</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lefr&#x000e8;re</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lichtin</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Tarantino</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Terebelo</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Viallard</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Cuevas</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Go</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Henry</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Redner</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Rice</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schipperus</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Nichol</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.</article-title>
            <source>Lancet</source>
            <year>2008</year>
            <month>Feb</month>
            <day>02</day>
            <volume>371</volume>
            <issue>9610</issue>
            <fpage>395</fpage>
            <page-range>395-403</page-range>
            <pub-id pub-id-type="pmid">18242413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Samkari</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kuter</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia.</article-title>
            <source>Ther Adv Hematol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>2040620719841735</fpage>
            <pub-id pub-id-type="pmid">31007886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peck-Radosavljevic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Iacobellis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hassanein</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kayali</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Makara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ben Ari</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mitrut</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Akdogan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pirisi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Duggal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ochiai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Motomiya</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nagata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Afdhal</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).</article-title>
            <source>Hepatology</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>70</volume>
            <issue>4</issue>
            <fpage>1336</fpage>
            <page-range>1336-1348</page-range>
            <pub-id pub-id-type="pmid">30762895</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuter</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Bussel</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Newland</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Wasser</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Viallard</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Macik</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rummel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nie</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jun</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.</article-title>
            <source>Br J Haematol</source>
            <year>2013</year>
            <month>May</month>
            <volume>161</volume>
            <issue>3</issue>
            <fpage>411</fpage>
            <page-range>411-23</page-range>
            <pub-id pub-id-type="pmid">23432528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allred</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Bowen</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Wire</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>72</volume>
            <issue>2</issue>
            <fpage>321</fpage>
            <page-range>321-9</page-range>
            <pub-id pub-id-type="pmid">21434975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Wire</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Kapsi</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies.</article-title>
            <source>Clin Ther</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>764</fpage>
            <page-range>764-76</page-range>
            <pub-id pub-id-type="pmid">19446149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nomoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zamora</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Schuck</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Boyd</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Aluri</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Siu</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Yasuda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ferry</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rege</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2018</year>
            <month>May</month>
            <volume>84</volume>
            <issue>5</issue>
            <fpage>952</fpage>
            <page-range>952-960</page-range>
            <pub-id pub-id-type="pmid">29341245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stoeva</surname>
                <given-names>NY</given-names>
              </name>
              <name>
                <surname>Koleva</surname>
                <given-names>VS</given-names>
              </name>
            </person-group>
            <article-title>Homozygous Carrier of Prothrombin G20210A Mutation with Massive Pulmonary Embolism and His Family: Gender Differences of Susceptibility to Mutation.</article-title>
            <source>Folia Med (Plovdiv)</source>
            <year>2016</year>
            <month>Mar</month>
            <day>01</day>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>64</fpage>
            <page-range>64-6</page-range>
            <pub-id pub-id-type="pmid">27383881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fukuda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nishioka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Superior Mesenteric Venous Thrombosis Associated with Protein C Deficiency.</article-title>
            <source>Intern Med</source>
            <year>2023</year>
            <month>Oct</month>
            <day>15</day>
            <volume>62</volume>
            <issue>20</issue>
            <fpage>3087</fpage>
            <page-range>3087-3088</page-range>
            <pub-id pub-id-type="pmid">36889707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Middeldorp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nieuwlaat</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Baumann Kreuziger</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Coppens</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Houghton</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moll</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chai-Adisaksopha</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Colunga-Lozano</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Karam</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wiercioch</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sch&#x000fc;nemann</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Iorio</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing.</article-title>
            <source>Blood Adv</source>
            <year>2023</year>
            <month>Nov</month>
            <day>28</day>
            <volume>7</volume>
            <issue>22</issue>
            <fpage>7101</fpage>
            <page-range>7101-7138</page-range>
            <pub-id pub-id-type="pmid">37195076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Diggele</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Burgess</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mellis</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Interprofessional education: tips for design and implementation.</article-title>
            <source>BMC Med Educ</source>
            <year>2020</year>
            <month>Dec</month>
            <day>03</day>
            <volume>20</volume>
            <issue>Suppl 2</issue>
            <fpage>455</fpage>
            <pub-id pub-id-type="pmid">33272300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeller</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Laureano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khandelwal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Haspel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fung</surname>
                <given-names>M</given-names>
              </name>
              <collab>BEST Collaborative</collab>
            </person-group>
            <article-title>Optimizing Informed Consent Discussions: Developing a Narrative for Transfusion Consent.</article-title>
            <source>Transfus Med Rev</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>150757</fpage>
            <pub-id pub-id-type="pmid">37741794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151158.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sandhu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Drug-Induced Liver Injury in GI Practice.</article-title>
            <source>Hepatol Commun</source>
            <year>2020</year>
            <month>May</month>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>631</fpage>
            <page-range>631-645</page-range>
            <pub-id pub-id-type="pmid">32363315</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
